PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers
NCT05232006
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
Interventions
DRUG:
Niraparib
Sponsor
Assistance Publique - Hôpitaux de Paris